Intellia Therapeutics (38I) Price & Analysis

Compare

13 Followers

38I Stock Chart & Stats

€7.98

-€0.50(-4.02%)

At close: Jan 08 4:00 PM EST

€7.98

-€0.50(-4.02%)

Day’s Range― - ―

52-Week Range€5.30 - €24.34

Previous CloseN/A

Volume0.00

Average Volume (3M)1.56K

Market Cap

$955.85M

Enterprise Value€1.49B

Total Cash (Recent Filing)$511.04M

Total Debt (Recent Filing)$97.97M

Price to Earnings (P/E)―

Beta1.70

Next Earnings

Feb 19, 2026

EPS Estimate

-0.83

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.79

Shares Outstanding115,829,926

10 Day Avg. Volume922

30 Day Avg. Volume1,564

Financial Highlights & Ratios

PEG Ratio0.71

Price to Book (P/B)1.32

Price to Sales (P/S)19.91

P/FCF Ratio-3.25

Enterprise Value/Market Cap1.56

Enterprise Value/Revenue25.90

Enterprise Value/Gross Profit-69.55

Enterprise Value/Ebitda-3.27

Forecast

1Y Price Target

$13.72

Price Target Upside71.97% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering22

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Efficacy DataEfficacy data has looked impressive for nex-z, with durable reductions in TTR and functional benefits noted in the phase 1 trial in ATTR-CM.

Financial PositionStrong financial position, with cash runway into 2027, supports key milestones while maintaining operational efficiency.

Market DemandLonvo-z’s explosive enrollment speed signals massive demand for one-time HAE therapy, establishing clear floor.

Bears Say

Clinical Hold ImpactIntellia shares have been under repeated pressure in the aftermath of a severe liver tox event on their ATTR-CM program, which culminated in a clinical hold and the death of a patient.

Regulatory ChallengesThe FDA might put a black box warning on TTR, diminishing competitiveness against rivals and causing slower enrollment and cash generation.

Safety ConcernsNex-z's safety issue neutralizes bullish arguments, and the stock is expected to become fragile as investors will likely be intolerant of the FDA hold.

Intellia Therapeutics News

Citizens JMP healthcare analysts hold an analyst/industry conference

Healthcare Analysts discuss regulatory landscape for AAV-based gene therapies (relevant companies (SLDB, TSHA, BNTC, SRPT, QURE, NTLA, CRSP,...

20d ago

BNTC

CRSP

Midday Fly By: AMD sees acceleration, IBM unveils quantum processor

The major averages were mixed near noon, with the Dow Jones Industrial Average hitting a record high as...

26d ago

Carvana initiated, AT&T upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

26d ago

Wolfe downgrades Intellia to Peer Perform on Nex-z safety issue

Wolfe Research last night downgraded Intellia Therapeutics (NTLA) to Peer Perform from Outperform without a price target The...

26d ago

NTLA

Intellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research analyst Andy Chen downgraded Intellia Therapeutics (NTLA) to Peer Perform from Outperform. Published first on TheFly...

27d ago

NTLA

FDA appoints Richard Pazdur as Director of CDER

The U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced that Richard...

27d ago

AZN

BMY

Intellia Therapeutics downgraded to Hold from Buy at JonesResearch

JonesResearch downgraded Intellia Therapeutics (NTLA) to Hold from Buy after the company reported along with Q3 results on...

27d ago

NTLA

Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI

Evercore ISI downgraded Intellia Therapeutics (NTLA) to In Line from Outperform with a price target of $8, down...

27d ago

NTLA

Intellia announces ‘positive’ follow-up data from ongoing Phase 1 nex-z trial

Intellia Therapeutics (NTLA) announced “positive” follow-up data from the ongoing Phase 1 clinical trial of its investigational product...

28d ago

NTLA

Intellia Therapeutics price target lowered to $14 from $25 at Truist

Truist lowered the firm’s price target on Intellia Therapeutics (NTLA) to $14 from $25 but keeps a Buy...

28d ago

NTLA

Cathie Wood Sells Tesla (TSLA) Stock, and Buys This Stock after Q3 Beat

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Friday, November 7, according to daily fund...

28d ago

TTD

BEAM

Algonquin, Spotify, Keysight, Intellia, CoreWeave: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($AQN) ), ( ($SPOT) ), ( ($KEYS) ), ( ($NTLA)...

23d ago

AQN

CRWV

Intellia Therapeutics Reports Q3 2025 Financial Results

Intellia Therapeutics Inc ( ($NTLA) ) has released its Q3 earnings. Here is a breakdown of the information...

25d ago

NTLA

Intellia Reports Favorable Phase 1 Data for Nex-Z

Intellia Therapeutics ( ($NTLA) ) has provided an update. On November 8, 2025, Intellia Therapeutics announced positive results...

28d ago

NTLA

38I FAQ

What was Intellia Therapeutics’s price range in the past 12 months?

Intellia Therapeutics lowest stock price was €5.30 and its highest was €24.34 in the past 12 months.

What is Intellia Therapeutics’s market cap?

Intellia Therapeutics’s market cap is $955.85M.

When is Intellia Therapeutics’s upcoming earnings report date?

Intellia Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 73 days.

How were Intellia Therapeutics’s earnings last quarter?

Intellia Therapeutics released its earnings results on Nov 06, 2025. The company reported -€0.793 earnings per share for the quarter, beating the consensus estimate of -€0.867 by €0.073.

Is Intellia Therapeutics overvalued?

According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Intellia Therapeutics pay dividends?

Intellia Therapeutics does not currently pay dividends.

What is Intellia Therapeutics’s EPS estimate?

Intellia Therapeutics’s EPS estimate is -0.83.

How many shares outstanding does Intellia Therapeutics have?

Intellia Therapeutics has 115,829,926 shares outstanding.

What happened to Intellia Therapeutics’s price movement after its last earnings report?

Intellia Therapeutics reported an EPS of -€0.793 in its last earnings report, beating expectations of -€0.867. Following the earnings report the stock price went down -31.033%.

Which hedge fund is a major shareholder of Intellia Therapeutics?

Currently, no hedge funds are holding shares in DE:38I

Intellia Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-52.11%

Trailing 12-Months

Asset Growth

-21.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics (38I) Earnings & Revenues

Historic Earnings Reports

38I Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Negative

The earnings call presented a mix of progress and challenges. While significant advancements were made in the lonvo-z program and financial stability was maintained, the clinical hold on nex-z trials due to patient safety concerns significantly impacted the company's outlook. The sentiment is largely influenced by the serious nature of the clinical hold and patient safety issues.View all DE:38I earnings summaries

38I Revenue Breakdown

100.00% Collaboration revenue

38I Stock 12 Month Forecast

Average Price Target

€13.72

▲(71.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","47":"€47","13.25":"€13.25","24.5":"€24.5","35.75":"€35.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46.40379192,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€46.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.7234917956,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€13.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.43731792,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.44</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,13.25,24.5,35.75,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.485,13.247983993846153,16.010967987692307,18.77395198153846,21.536935975384615,24.29991996923077,27.062903963076923,29.825887956923076,32.58887195076923,35.35185594461539,38.11483993846154,40.87782393230769,43.64080792615385,{"y":46.40379192,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.485,10.734114753507692,10.983229507015384,11.232344260523076,11.481459014030769,11.730573767538461,11.979688521046153,12.228803274553846,12.477918028061538,12.72703278156923,12.976147535076922,13.225262288584615,13.474377042092307,{"y":13.7234917956,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.485,9.942870609230768,9.400741218461539,8.858611827692307,8.316482436923076,7.774353046153846,7.232223655384615,6.690094264615384,6.147964873846154,5.605835483076923,5.063706092307692,4.521576701538462,3.979447310769231,{"y":3.43731792,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.525,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.06,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.952,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.234,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.522,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.752,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.384,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.485,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >